We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 37% in a year while the S&P 500 rose 15%.
| Latest filing | 8-K, Oct 29 |
TodayOn a down day.
After its last 4 reports it closed +0.1% on average, higher 3 of 4 times.
Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
PEN is #67 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 67 |
Net income over four quarters: PEN $161M, SYK $3.73B, DXCM $1.00B, MMSI $146M.
Expected to report Wed Feb 24, after the close (in 111 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $410.1M, 16% more than a year ago; a profit of $1.07 a share, from $1.17.
PEN's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
Sales grew 20% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 1.9% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 29, 2026 | -0.4% | -0.9% | -0.3% |
| Jul 30, 2026 | +1.0% | +0.4% | +1.6% |
| May 6, 2026 | -0.1% | +0.1% | -0.5% |
Sales grew every year from 2018 to 2025, to $1.4B. It made a profit in six of the eight years.
3 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: PEN is under 0.1% of SCHG and under 0.1% of VTI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
“The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants.”
PEN scores 0 today, which Breakaway calls Below Average. It is #67 of 85 in Medical Devices by Quality Score, with 3 of 14 chart checks firing. Up 37% in a year while the S&P 500 rose 15%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PEN scores 0 today, which Breakaway calls Below Average (0 to 5). That is #67 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PEN's 0.
Expected to report Wed Feb 24, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. PEN closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.